Two months after the second HyperCVAD cycle, the disease relapsed and the patient was treated with chemotherapy per the Northern Italy Leukemia Group ALL 10/07 trial.14 A repeated marrow examination after 2 months showed persistent ETP ALL, and the patient was further treated with an anti-CD52 monoclonal antibody12 for a cumulative dose of 100 mg, without benefit. The gene discussed is CD52; the disease is acute lymphoblastic leukemia.